Primary membranous nephropathy (PMN) is a kidney-specific, progressive, autoimmune disease primarily characterized by high proteinuria. Based on multiple clinical factors, such as proteinuria, PMN patients are generally classified as low, moderate, or high risk. Most patients respond adequately to conservative / supportive treatments and to immunosuppressants; however, there is a significant unmet need for better treatments for patients at high risk of disease progression to end-stage renal disease. The FDA has not approved any therapies for PMN, but the pipeline has several agents with various mechanisms of action in early-phase development.
Geography: United States
Primary Research: 3 KOL interviews in June 2020
Key Companies Covered: Apellis, GlaxoSmithKline, Mallinckrodt, MorphoSys, Novartis, Omeros, Roche.
Key Drugs Covered: Acthar gel, belimumab (SC) and rituximab (IV), LNP-023, MOR-202, narsoplimab (OMS-721), pegcetacoplan (APL-2), Rituxan.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.